| Title |
Publication Date |
Price |
Relevance |
Discovery Stage Partnering Agreements in Biopharma
|
September 2008 |
£1195 |
96 % |
Clinical Stage Partnering Agreements in Biopharma
|
June 2008 |
£1195 |
96 % |
Pre-clinical Stage Partnering Agreements in Biopharma
|
October 2008 |
£1195 |
96 % |
Partnering Agreements with Amgen 2010
|
January 2010 |
£295 |
50 % |
Partnering Agreements with Allergan 2010
|
January 2010 |
£295 |
50 % |
Partnering Agreements with Alcon 2010
|
January 2010 |
£295 |
50 % |
Bigpharma Dealmaking Handbook
Companies & Contacts
|
September 2008 |
£1195 |
44.5 % |
Bigpharma Partnering Agreements
|
March 2008 |
£1195 |
39.5 % |
Partnering Agreements with Hospira
2010
|
January 2010 |
£295 |
38.5 % |
Partnering Agreements with Gilead
2010
|
January 2010 |
£295 |
38.5 % |
Partnering Agreements with Genzyme
2010
|
January 2010 |
£295 |
38.5 % |
Partnering Agreements with Johnson Johnson
2010
|
January 2010 |
£295 |
38.5 % |
Partnering Agreements with LundBeck
2010
|
January 2010 |
£295 |
38.5 % |
Partnering Agreements with Merck & Co
2010
|
January 2010 |
£295 |
38.5 % |
Partnering Agreements with Menarini
2010
|
January 2010 |
£295 |
38.5 % |
Partnering Agreements with Genentech
2010
|
January 2010 |
£295 |
38.5 % |
Partnering Agreements with Galxosmithkline
2010
|
January 2010 |
£295 |
38.5 % |
Partnering Agreements with Merck Serono
2010
|
January 2010 |
£295 |
38 % |
Partnering Agreements with CSL 2010
|
January 2010 |
£295 |
37 % |
Partnering Agreements with Abbott 2010
|
January 2010 |
£295 |
37 % |
Partnering Agreements with Actavis 2010
|
January 2010 |
£295 |
37 % |
Bigpharma Agreements Handbook
Partnering Agreements
|
September 2008 |
£1195 |
37 % |
Partnering Agreements with UCB 2010
|
January 2010 |
£295 |
37 % |
Partnering Agreements with Baxter 2010
|
January 2010 |
£295 |
36.5 % |
Partnering Agreements with Bayer 2010
|
January 2010 |
£295 |
36.5 % |
Partnering Agreements with Eisai 2010
|
January 2010 |
£295 |
36.5 % |
ScheringPlough Partnering Guide 2008
|
July 2008 |
£195 |
36.5 % |
Wyeth Partnering Guide 2008
|
July 2008 |
£195 |
36.5 % |
Partnering Agreements with Eli Lilly 2010
|
January 2010 |
£295 |
36.5 % |
Partnering Agreements with AstraZeneca 2010
|
January 2010 |
£295 |
36.5 % |
Partnering Agreements with Dainippon Sumitomo 2010
|
January 2010 |
£295 |
36.5 % |
Partnering Agreements with Daiichi Sankyo 2010
|
January 2010 |
£295 |
36.5 % |
ProcterGamble Partnering Guide 2008
|
July 2008 |
£195 |
36.5 % |
Partnering Agreements with Biogen Idec 2010
|
January 2010 |
£295 |
36.5 % |
Partnering Agreements with Cephalon 2010
|
January 2010 |
£295 |
36.5 % |
Partnering Agreements with Astellas 2010
|
January 2010 |
£295 |
36.5 % |
Partnering Agreements with Boehringer Ingelheim 2010
|
January 2010 |
£295 |
36.5 % |
Partnering Agreements with Chugai 2010
|
January 2010 |
£295 |
36.5 % |
GlaxoSmithKline Partnering Guide 2008
|
July 2008 |
£195 |
36.5 % |
Partnering Agreements with Pfizer 2010
|
January 2010 |
£295 |
36.5 % |
Partnering Agreements with Ratiopharm 2010
|
January 2010 |
£295 |
36.5 % |
Partnering Agreements with Otsuka 2010
|
January 2010 |
£295 |
36.5 % |
King Partnering Guide 2008
|
July 2008 |
£195 |
36.5 % |
Partnering Agreements with Novo Nordisk 2010
|
January 2010 |
£295 |
36.5 % |
Partnering Agreements with Roche 2010
|
January 2010 |
£295 |
36.5 % |
Partnering Agreements with Servier 2010
|
January 2010 |
£295 |
36.5 % |
Partnering Agreements with Teva 2010
|
January 2010 |
£295 |
36.5 % |
Partnering Agreements with Watson 2010
|
January 2010 |
£295 |
36.5 % |
Partnering Agreements with Takeda 2010
|
January 2010 |
£295 |
36.5 % |
Partnering Agreements with Solvay 2010
|
January 2010 |
£295 |
36.5 % |
Partnering Agreements with Shire 2010
|
January 2010 |
£295 |
36.5 % |
Partnering Agreements with Novartis 2010
|
January 2010 |
£295 |
36.5 % |
Partnering Agreements with Nycomed 2010
|
January 2010 |
£295 |
36.5 % |
Mundipharma Partnering Guide 2008
|
July 2008 |
£195 |
36.5 % |
Abbott Labs Partnering Guide 2008
|
July 2008 |
£195 |
36.5 % |
Partnering Agreements with Mylan 2010
|
January 2010 |
£295 |
36.5 % |
Stada Partnering Guide 2008
|
July 2008 |
£195 |
36.5 % |
Alcon Labs Partnering Guide 2008
|
July 2008 |
£195 |
36.5 % |
Allergan Partnering Guide 2008
|
July 2008 |
£195 |
36.5 % |
Partnering Agreements with Mitsubishi Tanabe 2010
|
January 2010 |
£295 |
36.5 % |
Actavis Pharma Partnering Guide 2008
|
July 2008 |
£195 |
36.5 % |
Partnering Agreements with Forest 2010
|
January 2010 |
£295 |
36.5 % |
Amgen Partnering Guide 2008
|
July 2008 |
£195 |
36.5 % |
Partnering Agreements with Bristol-Myers Squibb 2010
|
January 2010 |
£295 |
36 % |
Barr Pharmaceuticals Partnering Guide 2008
|
July 2008 |
£195 |
36 % |
Partnering Agreements with Sanofi-Aventis 2010
|
January 2010 |
£295 |
35.5 % |
Partnering Agreements with Bigpharma
|
February 2010 |
£1395 |
35.5 % |
Indian Biopharmaceuticals Industry Report
|
January 2007 |
£400 |
34.65 % |
Royalty Financing Agreements in Pharma, Biotech and Diagnostics
|
January 2009 |
£495 |
34.5 % |
Bigpharma Dealmaking and Agreements Handbook 2007
Companies, Contacts & Partnering Agreements
|
September 2007 |
£1195 |
34 % |
The Future of Metabolomics
Building competitive advantage in drug discovery, clinical development and diagnostics
|
August 2006 |
£1495 |
31.5 % |
Oncology Partnering Agreements in Pharma, Biotech and Diagnostics
|
June 2009 |
£1195 |
30.8 % |
Partnering Agreements In Diagnostics
Trends in diagnostics partnering deals
|
September 2009 |
£1195 |
30 % |
Practical Guide to Finding Partners in Pharma and Biotech
2nd edition
|
April 2009 |
£695 |
29.75 % |
Merger and Acquisition Agreements in Pharma, Biotech and Diagnostics
|
March 2010 |
£1495 |
29.75 % |
Indian Biopharmaceuticals
|
January 2008 |
£600 |
29.4 % |
Practical Guide to Finding Partners in Biopharma
|
November 2007 |
£495 |
29.4 % |
AVI Biopharma, Inc.-Deals & Alliances Report
|
January 2010 |
£395 |
28.5 % |
Integrated Biopharma Inc. -Deals & Alliances Report
|
February 2008 |
£200 |
28.5 % |
DOR BioPharma, Inc. -Deals & Alliances Report
|
February 2008 |
£200 |
28.5 % |
Array BioPharma, Inc. -Deals & Alliances Report
|
February 2008 |
£200 |
28.5 % |
AVI Biopharma, Inc. -Deals & Alliances Report
|
February 2008 |
£200 |
28.5 % |
PDL BioPharma Inc. -Deals & Alliances Report
|
February 2008 |
£200 |
28.5 % |
Hemispherx Biopharma, Inc. -Deals & Alliances Report
|
February 2008 |
£200 |
28.5 % |
Array BioPharma, Inc.-Deals & Alliances Report
|
January 2010 |
£395 |
28.5 % |
PDL BioPharma, Inc.-Deals & Alliances Report
|
January 2010 |
£395 |
28.5 % |
Drug Delivery Partnering Agreements In Pharma & Biotech
|
October 2009 |
£1195 |
27.3 % |
Purdue Pharma LP Deals
Partneringdesk briefing
|
July 2005 |
£215 |
27 % |
Co-Promotion & Co-Marketing Agreements in Pharma, Biotech and Diagnostics
|
February 2010 |
£1495 |
25 % |
Manufacturing & Supply Agreements in Pharma, Biotech and Diagnostics
2nd Edition
|
July 2009 |
£1195 |
24.5 % |
Partneringdesk deals and alliances in infectious diseases
|
April 2006 |
£1250 |
23.5 % |
Distribution Agreements in Pharma, Biotech and Diagnostics
2nd edition
|
March 2010 |
£1495 |
23 % |
Product and Asset Purchase Agreements in Pharma, Biotech and Diagnostics
|
November 2008 |
£1195 |
21.5 % |
Option & Evaluation Agreements in Pharma and Biotech
|
March 2009 |
£995 |
20.65 % |
The Handbook on Alliances & Deals in Biotech Business
|
May 2004 |
£445 |
18.55 % |
Winning R&D Productivity Strategies
Exploiting innovation, licensing and outsourcing opportunities
|
October 2006 |
£1495 |
12.6 % |
Partneringreview 2006 - Company Deal Index
Volume 1
|
February 2006 |
£1395 |
12.5 % |
The China Pharmaceutical Market: A Strategic Opportunity Analysis
|
January 2007 |
£840 |
12.25 % |
Partneringreview 2006
|
February 2006 |
£2195 |
12 % |
Competitive Outlook on HCV
What to Know & Expect in R&D and Business Development
|
June 2004 |
£895 |
11.9 % |
Partneringreview 2006 – Financings
Volume 3
|
February 2006 |
£1395 |
11.5 % |
Partneringreview 2006 – Therapy Area
Volume 2
|
February 2006 |
£1395 |
11 % |
Partneringreview 2006 – Stage of Development
Volume 4
|
February 2006 |
£1395 |
11 % |
Partneringreview 2006 – Deal Type
Volume 5
|
February 2006 |
£1395 |
11 % |
Partneringreview 2006 – Industry Sector
Volume 6
|
February 2006 |
£1395 |
11 % |
Pipeline Insight: Hematological Malignancies Companies target niche indications to facilitate market entry
|
April 2009 |
£3965 |
8.05 % |
